Display options
Cite
Mitchell JL, Pollara J, Dietze K, et al. Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. J Clin Invest. 2022;132(1)doi: 10.1172/JCI150937.
Mitchell, J. L., Pollara, J., Dietze, K., Edwards, R. W., Nohara, J., N'guessan, K. F., Zemil, M., Buranapraditkun, S., Takata, H., Li, Y., Muir, R., Kroon, E., Pinyakorn, S., Jha, S., Manasnayakorn, S., Chottanapund, S., Thantiworasit, P., Prueksakaew, P., Ratnaratorn, N., Nuntapinit, B., Fox, L., Tovanabutra, S., Paquin-Proulx, D., Wieczorek, L., Polonis, V. R., Maldarelli, F., Haddad, E. K., Phanuphak, P., Sacdalan, C. P., Rolland, M., Phanuphak, N., Ananworanich, J., Vasan, S., Ferrari, G., Trautmann, L. (2022). Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. The Journal of clinical investigation, 132(1), . https://doi.org/10.1172/JCI150937
Mitchell, Julie L, et al. "Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection." The Journal of clinical investigation vol. 132,1 (2022). doi: https://doi.org/10.1172/JCI150937
Mitchell JL, Pollara J, Dietze K, Edwards RW, Nohara J, N'guessan KF, Zemil M, Buranapraditkun S, Takata H, Li Y, Muir R, Kroon E, Pinyakorn S, Jha S, Manasnayakorn S, Chottanapund S, Thantiworasit P, Prueksakaew P, Ratnaratorn N, Nuntapinit B, Fox L, Tovanabutra S, Paquin-Proulx D, Wieczorek L, Polonis VR, Maldarelli F, Haddad EK, Phanuphak P, Sacdalan CP, Rolland M, Phanuphak N, Ananworanich J, Vasan S, Ferrari G, Trautmann L. Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. J Clin Invest. 2022 Jan 04;132(1). doi: 10.1172/JCI150937. PMID: 34762600; PMCID: PMC8718150.
Copy Download .nbib Format: NLM
Share it on

J Clin Invest. 2022 Jan 04;132(1). doi: 10.1172/JCI150937.

Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.

The Journal of clinical investigation

Julie L Mitchell, Justin Pollara, Kenneth Dietze, R Whitney Edwards, Junsuke Nohara, Kombo F N'guessan, Michelle Zemil, Supranee Buranapraditkun, Hiroshi Takata, Yifan Li, Roshell Muir, Eugene Kroon, Suteeraporn Pinyakorn, Shalini Jha, Sopark Manasnayakorn, Suthat Chottanapund, Pattarawat Thantiworasit, Peeriya Prueksakaew, Nisakorn Ratnaratorn, Bessara Nuntapinit, Lawrence Fox, Sodsai Tovanabutra, Dominic Paquin-Proulx, Lindsay Wieczorek, Victoria R Polonis, Frank Maldarelli, Elias K Haddad, Praphan Phanuphak, Carlo P Sacdalan, Morgane Rolland, Nittaya Phanuphak, Jintanat Ananworanich, Sandhya Vasan, Guido Ferrari, Lydie Trautmann,

Affiliations

  1. Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA.
  2. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  3. Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, Maryland, USA.
  4. Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  5. Department of Medicine and.
  6. Center of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  7. Department of Medicine, Division of Infectious Diseases and HIV Medicine, Drexel University, Philadelphia, Pennsylvania, USA.
  8. Institute of HIV Research and Innovation (IHRI), Bangkok, Thailand.
  9. Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand.
  10. Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand.
  11. Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  12. HIV Dynamics and Replication Program, National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.
  13. Department of Global Health, University of Amsterdam, Amsterdam, Netherlands.

PMID: 34762600 PMCID: PMC8718150 DOI: 10.1172/JCI150937

Abstract

Early initiation of antiretroviral therapy (ART) in acute HIV infection (AHI) is effective at limiting seeding of the HIV viral reservoir, but little is known about how the resultant decreased antigen load affects long-term Ab development after ART. We report here that Env-specific plasma antibody (Ab) levels and Ab-dependent cellular cytotoxicity (ADCC) increased during the first 24 weeks of ART and correlated with Ab levels persisting after 48 weeks of ART. Participants treated in AHI stage 1 had lower Env-specific Ab levels and ADCC activity on ART than did those treated later. Importantly, participants who initiated ART after peak viremia in AHI developed elevated cross-clade ADCC responses that were detectable 1 year after ART initiation, even though clinically undetectable viremia was reached by 24 weeks. These data suggest that there is more germinal center (GC) activity in the later stages of AHI and that Ab development continues in the absence of detectable viremia during the first year of suppressive ART. The development of therapeutic interventions that can enhance earlier development of GCs in AHI and Abs after ART initiation could provide important protection against the viral reservoir that is seeded in individuals treated early in the disease.

Keywords: AIDS/HIV; Immunoglobulins; Immunology

References

  1. J Gen Virol. 2001 Sep;82(Pt 9):2225-2234 - PubMed
  2. Annu Rev Immunol. 2012;30:429-57 - PubMed
  3. Sci Transl Med. 2014 Mar 19;6(228):228ra39 - PubMed
  4. Clin Infect Dis. 2016 Aug 15;63(4):555-61 - PubMed
  5. Nature. 2021 Mar;591(7851):639-644 - PubMed
  6. PLoS Pathog. 2016 Jan 08;12(1):e1005315 - PubMed
  7. J Virol. 2001 Aug;75(15):6953-61 - PubMed
  8. J R Soc Interface. 2021 Jun;18(179):20210314 - PubMed
  9. J Virol. 1996 Feb;70(2):1100-8 - PubMed
  10. J Exp Med. 2018 Sep 3;215(9):2311-2324 - PubMed
  11. Res Virol. 1994 May-Aug;145(3-4):221-7 - PubMed
  12. Retrovirology. 2013 May 29;10:56 - PubMed
  13. Sci Transl Med. 2019 Oct 9;11(513): - PubMed
  14. N Engl J Med. 2016 Jun 2;374(22):2120-30 - PubMed
  15. J Immunol. 2001 Jan 1;166(1):690-6 - PubMed
  16. Sci Rep. 2017 Oct 4;7(1):12655 - PubMed
  17. PLoS Pathog. 2020 Feb 5;16(2):e1008286 - PubMed
  18. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 - PubMed
  19. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32066-32077 - PubMed
  20. J Virol. 2008 Dec;82(24):12449-63 - PubMed
  21. JCI Insight. 2016 Jul 7;1(10): - PubMed
  22. Science. 1997 May 9;276(5314):960-4 - PubMed
  23. PLoS Pathog. 2016 Jul 27;12(7):e1005777 - PubMed
  24. Nat Med. 2013 Apr;19(4):494-9 - PubMed
  25. N Engl J Med. 2021 Mar 25;384(12):1089-1100 - PubMed
  26. PLoS One. 2012;7(3):e33948 - PubMed
  27. Sci Transl Med. 2020 Mar 4;12(533): - PubMed
  28. J Exp Med. 2011 Oct 24;208(11):2237-49 - PubMed
  29. AIDS. 2003 Sep 5;17(13):1871-9 - PubMed
  30. Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7 - PubMed
  31. Nat Commun. 2017 Jun 08;8:15711 - PubMed
  32. Pathog Immun. 2016 Spring;1(1):68-106 - PubMed
  33. J Clin Invest. 2019 Nov 1;129(11):4838-4849 - PubMed
  34. Cell Host Microbe. 2014 Aug 13;16(2):215-226 - PubMed
  35. Nat Med. 1998 Mar;4(3):341-5 - PubMed
  36. Nat Commun. 2019 Jun 21;10(1):2737 - PubMed
  37. J Immunol Methods. 2011 Mar 7;366(1-2):8-19 - PubMed
  38. J Clin Microbiol. 2003 Oct;41(10):4531-6 - PubMed
  39. Immunity. 2019 Aug 20;51(2):398-410.e5 - PubMed
  40. J Virol. 2014 Sep 1;88(17):10056-65 - PubMed
  41. N Engl J Med. 2012 Apr 5;366(14):1275-86 - PubMed
  42. J Virus Erad. 2016;2:43-48 - PubMed
  43. PLoS Pathog. 2020 Sep 3;16(9):e1008764 - PubMed
  44. PLoS One. 2014 Dec 29;9(12):e116306 - PubMed
  45. Immunology. 1965 Oct;9(4):349-57 - PubMed
  46. J Infect Dis. 2005 May 1;191(9):1410-8 - PubMed
  47. Cell Host Microbe. 2015 Sep 9;18(3):354-62 - PubMed
  48. J Virol. 2011 Jul;85(14):7029-36 - PubMed
  49. J Virol. 2005 Mar;79(5):2823-30 - PubMed
  50. J Biol Chem. 2001 Mar 2;276(9):6591-604 - PubMed
  51. J Cell Biol. 1978 Apr;77(1):148-64 - PubMed
  52. EBioMedicine. 2016 Sep;11:68-72 - PubMed
  53. PLoS Pathog. 2015 Dec 01;11(12):e1005285 - PubMed
  54. Immunity. 2013 Jun 27;38(6):1164-75 - PubMed
  55. J Clin Invest. 2002 Oct;110(8):1133-9 - PubMed
  56. J Virol. 2020 Jan 31;94(4): - PubMed
  57. Nature. 2003 Mar 20;422(6929):307-12 - PubMed
  58. J Immunol. 2005 May 1;174(9):5358-66 - PubMed
  59. J Virol. 2007 Jun;81(12):6187-96 - PubMed
  60. Virology. 2020 Sep;548:152-159 - PubMed
  61. Nat Med. 2018 Jul;24(7):923-926 - PubMed
  62. J Virol. 2014 Jul;88(14):7715-26 - PubMed
  63. Sci Transl Med. 2019 Nov 27;11(520): - PubMed
  64. Sci Transl Med. 2014 Mar 19;6(228):228ra38 - PubMed
  65. mBio. 2021 Mar 9;12(2): - PubMed
  66. J Clin Invest. 2020 Oct 1;130(10):5157-5170 - PubMed

Publication Types